Britain’s National Health Service is set to run tests on a CBD product that’s been on the market in the United Kingdom for over a year.
The test results could lead to further acceptance of medical cannabis in the U.K. and provide new opportunities for medical marijuana entrepreneurs.
The NHS will be testing the MediPen, a small, portable oil-based vaporizer that’s used to treat symptoms ranging from from depression to arthritis and fibromyalgia, according to the Independent.
“We’ve recently been working very closely with a team of NHS production and regulatory support pharmacists,” MediPen Managing Director Jordan Owen told the newspaper.
CBD is also an ingredient in the GW Pharmaceuticals product Sativex, which is made for multiple sclerosis patients and is available via prescription in the UK.
But the MediPen tests could lead to both further evidence and acceptance of cannabis’ medicinal value in both the UK and other countries.